Financial Advantage’s Myriad Genetics MYGN Stock Holding History

Financial Advantage’s Portfolio MYGN Stock Details MYGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q4	–	Sell	-800	Closed	-$30K	–	80
2015 Q3	$30K	Hold	800	–	–	0.03%	70
2015 Q2	$27K	Hold	800	–	–	0.03%	73
2015 Q1	$28K	Hold	800	–	–	0.02%	70
2014 Q4	$27K	Hold	800	–	–	0.03%	67
2014 Q3	$31K	Hold	800	–	–	0.03%	67
2014 Q2	$31K	Hold	800	–	–	0.03%	68
2014 Q1	$27K	Hold	800	–	–	0.03%	71
2013 Q4	$17K	Hold	800	–	–	0.01%	114
2013 Q3	$19K	Hold	800	–	–	0.02%	103
2013 Q2	$21K	Buy	+800	New	+$23.2K	0.02%	96

Other funds holding MYGN

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

SCM

Scopia Capital Management New York $146M AUM 25.93% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

IAM

Iridian Asset Management Westport, Connecticut $247M AUM 20.65% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Financial Advantage's MYGN Position: Q4 2015 in Review

Financial Advantage sold out of Myriad Genetics (MYGN) in Q4 2015, closing a stake of 800 shares — an estimated $30K sold.

Financial Advantage first reported a position in MYGN in Q2 2013 and held it in 10 quarters. The position peaked at $31K in Q3 2014. 232 funds tracked by Wall St. Rank hold MYGN as of Q4 2015.

Financial Advantage reported no remaining Myriad Genetics position as of Q4 2015 after selling out during the quarter.
Financial Advantage sold 800 Myriad Genetics shares in Q4 2015, an estimated $30K.
Financial Advantage first reported a position in Myriad Genetics in Q2 2013 and held it in 10 quarters.
Financial Advantage's Myriad Genetics position peaked at $31K in Q3 2014.
232 funds tracked by Wall St. Rank held Myriad Genetics as of Q4 2015.

Based on Financial Advantage's 13F filing for Q4 2015, filed 29 Jan 2016.